Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma

被引：12
作者：
Han, Ji Won [1 ,2 ]
Jang, Jeong Won [1 ,2 ]
机构：
[1] Catholic Univ Korea, Catholic Univ Liver Res Ctr, Coll Med, Seoul 06591, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Gastroenterol & Hepatol, Seoul 06591, South Korea
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 14期
基金：
新加坡国家研究基金会;
关键词：
hepatocellular carcinoma; atezolizmumab-bevacizumab; biomarker; NEUTROPHIL-LYMPHOCYTE RATIO; PLUS BEVACIZUMAB; TUMOR; EXPRESSION; CELLS; INTERLEUKIN-6; MULTICENTER; COMBINATION; SUPPRESSION; SORAFENIB;
D O I：
10.3390/ijms241411799
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
A combination of atezolizumab with bevacizumab (AB) is the first regimen that has shown superiority compared to sorafenib and is now being used as the systemic treatment of choice for hepatocellular carcinoma (HCC) patients with Barcelona Liver Cancer Clinic stage C. However, a considerable number of patients do not achieve survival or significant responses, indicating the need to identify predictive biomarkers for initial and on-treatment decisions in HCC patients receiving AB. In this manuscript, we summarized the current data from both experimental and clinical studies. This review will be beneficial for both clinicians and researchers in clinical practice as well as those designing experimental, translational, or clinical studies.
引用
收藏
页数：22
相关论文
共 50 条
[21]   Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma [J].
Kuzuya, Teiji ;
Kawabe, Naoto ;
Hashimoto, Senju ;
Funasaka, Kohei ;
Nagasaka, Mitsuo ;
Nakagawa, Yoshihito ;
Miyahara, Ryoji ;
Shibata, Tomoyuki ;
Takahara, Takeshi ;
Kato, Yutaro ;
Sugioka, Atsushi ;
Hirooka, Yoshiki .
ANTICANCER RESEARCH, 2022, 42 (04) :1905-1910
[22]   Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma [J].
D'Alessio, Antonio ;
Cammarota, Antonella ;
Zanuso, Valentina ;
Pressiani, Tiziana ;
Personeni, Nicola ;
Rimassa, Lorenza .
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) :927-939
[23]   Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer [J].
Ventura, Ignacio ;
Sanchiz, Lorena ;
Legidos-Garcia, Maria Ester ;
Murillo-Llorente, Maria Teresa ;
Perez-Bermejo, Marcelino .
CANCERS, 2024, 16 (01)
[24]   RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab [J].
Kim, Dong Hwan ;
Min, Eun Jeong ;
Kim, Bohyun ;
Choi, Jong Young ;
Jang, Jeong Won ;
Sung, Pil Soo ;
Han, Ji Won ;
Kim, Hokun ;
Choi, Joon-Il .
EUROPEAN RADIOLOGY, 2025, 35 (02) :684-694
[25]   New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma [J].
Minot-This, Marie-Sophie ;
Edeline, Julien .
BULLETIN DU CANCER, 2021, 108 (02) :139-140
[26]   Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment [J].
Chen, Ching-Tso ;
Feng, Yin-Hsun ;
Yen, Chia-Jui ;
Chen, San-Chi ;
Lin, Yun-Tzu ;
Lu, Li-Chun ;
Hsu, Chih-Hung ;
Cheng, Ann-Lii ;
Shao, Yu-Yun .
HEPATOLOGY INTERNATIONAL, 2022, 16 (05) :1199-1207
[27]   Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma [J].
Cheon, Jaekyung ;
Yoo, Changhoon ;
Hong, Jung Yong ;
Kim, Han Sang ;
Lee, Dae-Won ;
Lee, Myung Ah ;
Kim, Jin Won ;
Kim, Ilhwan ;
Oh, Sang-Bo ;
Hwang, Jun-Eul ;
Chon, Hong Jae ;
Lim, Ho Yeong .
LIVER INTERNATIONAL, 2022, 42 (03) :674-681
[28]   Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma [J].
Li, Binghua ;
Wen, Jingyuan ;
Xu, Zhu ;
Yan, Peng ;
Han, Bing ;
Yu, Decai .
CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
[29]   Atezolizumab plus bevacizumab combination therapy compared to sorafenib and atezolizumab monotherapies for treatment of unresectable or metastatic hepatocellular carcinoma [J].
Ahmed, Faiza ;
Guntipalli, Prathima ;
Yukselen, Zeynep ;
Coronel, Maria-Kassandra ;
Zaidi, Madiha ;
Onwumeh-Okwundu, Jennifer ;
Garimella, Vamsi ;
Gudapati, Sravya ;
Mezidor, Marc-Darlene ;
Andrews, Kim ;
Mouchli, Mohamad ;
Shahini, Endrit ;
Mohan, Karthik .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 :69-70
[30]   Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma [J].
Zanuso, Valentina ;
Pirozzi, Angelo ;
Balsano, Rita ;
Pressiani, Tiziana ;
Rimassa, Lorenza .
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 :1689-1708
12345